Report : North America Vaccine Adjuvants Market Forecast to 2030 – Regional Analysis – by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
At 13.4% CAGR, North America Vaccine Adjuvants Market is Projected to be worth US$ 2,862.04 million by 2030, says Business Market Insights
According to Business Market Insights’ research, the North America vaccine adjuvants market was valued at US$ 1,044.84 million in 2022 and is expected to reach US$ 2,862.04 million by 2030, registering a CAGR of 13.4% from 2022 to 2030. Technological advancements and rising number of infectious disease outbreaks and pandemic are among the critical factors attributed to drive the North America vaccine adjuvants market growth.
Currently, aluminum salt or gel-based adjuvants are used predominantly in licensed vaccines in the US. Monophosphoryl lipid A (MPL) adjuvant and hydrophobic copolymers are examples of these components. Hydrophobic microspheres pose challenges during vaccine production. The problems include many environmental waste disposal and contamination issues and are time-consuming, costly, and inefficient. Therefore, manufacturers are emphasizing developing novel technologies to avoid using organic solvents. For example, Aphios’ Vaccine Adjuvant Technology encompasses nanotechnology, and its production includes supercritical, critical, or near-critical fluids with or without polar cosolvents such as ethanol [referred to as superfluids (SFS)]. Biodegradable biopolymers are dissolved in SFS and mixed with subunit vaccines in an aqueous solution or as a slurry of nanoparticles. Therefore, such new vaccine adjuvant technologies are being developed for making biodegradable polymer nanospheres (PNS) through novel processes, which allows vaccine manufacturers to rule out the use of organic solvents. Thus, technological advancements will likely bring new trends in the vaccine adjuvants market in the coming years.
On the contrary, product recalls and adverse effects hampers the growth of North America vaccine adjuvants market.
Based adjuvant class, the North America vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held 39.9% share of North America vaccine adjuvants market share in 2022, amassing US$ 422.79 million. It is projected to garner US$ 1,105.78 million by 2030 to register 12.8% CAGR during 2022–2030.
By type, the North America vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held 62.8% share of North America vaccine adjuvants market in 2022, amassing US$ 656.08 million. It is anticipated to garner US$ 1,838.01 million by 2030 to expand at 13.7% CAGR during 2022–2030.
By country, the North America vaccine adjuvants market is segmented into the US, Canada, and Mexico. The US segment held 84.7% share of North America vaccine adjuvants market in 2022, amassing US$ 885.19 million. It is anticipated to garner US$ 2,468.22 million by 2030 to expand at 13.7% CAGR during 2022–2030
Key players operating in the North America vaccine adjuvants market are Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc, among others.
- October, 2023; SPI Pharma Inc and Q-Vant Biosciences Inc announced a partnership that combines Q-Vant's leadership in sustainable saponin extraction technology with SPI's global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in expanding Q-Vant’s proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com